Entering text into the input field will update the search result below

Clene: Nanomedicines For Neurodegenerative Diseases

Aug. 03, 2021 10:08 AM ETClene Inc. (CLNN)5 Comments


  • Clene is a developer of proprietary, patented, nanocatalysis therapy for neurodegenerative diseases.
  • They have ongoing phase 2 trials in multiple sclerosis, Parkinson’s disease and amyotrophic lateral sclerosis.
  • Current stock price near 52-week low offers decent opening.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Melting brain
PM Images/DigitalVision via Getty Images


Clene Inc. (NASDAQ:CLNN) is a Salt Lake City, Utah based clinical-stage biopharmaceutical company presently focused on the discovery, development, and commercialization of treatments for neurodegenerative diseases with high unmet needs, specifically, multiple sclerosis (MS), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (AML) or

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research

Disclaimer - we are not investment advisors.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

Good overview

Stock is POS... likely a scam co incorporated in Utah.

I was a seller as soon as I saw nanometer, gold, platinum, and related party supplement company.

They are now closing phase 2 trial early for MS and blaming covid, which is crap, no other major covid trial has had weak enrollment,

Fyi slow enrollment until clinical trials is often a sign doctors are not referring patients into trials, bc doctors are skeptical.
sspencer profile picture
amyotrophic lateral sclerosis is not AML
Avisol Capital Partners profile picture
@sspencer You are right, should have been ALS, of course.
Difficult to start a position knowing a secondary is practically a certainty. Will keep an eye for this one when trial results come out.
Great long term play!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.